A composition comprising at least two compounds which induce indolamine 2,3-dioxygenase (IDO) for the treatment of an autoimmune disorder or immune rejection of organs.
The invention relates to the use of a composition comprising at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein said inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.